Clinical trial
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants…
NCT06131398 · Amgen, Industry · Active, not recruiting
Key facts
| NCT number | NCT06131398 |
|---|---|
| Title | A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors |
| Official title | A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors |
| Lead sponsor | Amgen, Industry |
| Status | Active, not recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Solid Tumors |
| Intervention type | Drug |
| Interventions | AMG 355, Pembrolizumab |
| Enrollment | 77 |
| Start date | Mar 7, 2024 |
| Primary completion | May 24, 2026 |
| Completion | Aug 3, 2026 |
| First posted | Nov 14, 2023 |
| Last update posted | Dec 22, 2025 |
| Countries | Australia, Canada, France, Japan, Netherlands, Poland, South Korea, Spain, Switzerland, Taiwan, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: